LPS-Induced Coagulation and Neuronal Damage in a Mice Model Is Attenuated by Enoxaparin

Int J Mol Sci. 2022 Sep 9;23(18):10472. doi: 10.3390/ijms231810472.

Abstract

Background. Due to the interactions between neuroinflammation and coagulation, the neural effects of lipopolysaccharide (LPS)-induced inflammation (1 mg/kg, intraperitoneal (IP), n = 20) and treatment with the anti-thrombotic enoxaparin (1 mg/kg, IP, 15 min, and 12 h following LPS, n = 20) were studied in C57BL/6J mice. Methods. One week after LPS injection, sensory, motor, and cognitive functions were assessed by a hot plate, rotarod, open field test (OFT), and Y-maze. Thrombin activity was measured with a fluorometric assay; hippocampal mRNA expression of coagulation and inflammation factors were measured by real-time-PCR; and serum neurofilament-light-chain (NfL), and tumor necrosis factor-α (TNF-α) were measured by a single-molecule array (Simoa) assay. Results. Reduced crossing center frequency was observed in both LPS groups in the OFT (p = 0.02), along with a minor motor deficit between controls and LPS indicated by the rotarod (p = 0.057). Increased hippocampal thrombin activity (p = 0.038) and protease-activated receptor 1 (PAR1) mRNA (p = 0.01) were measured in LPS compared to controls, but not in enoxaparin LPS-treated mice (p = 0.4, p = 0.9, respectively). Serum NfL and TNF-α levels were elevated in LPS mice (p < 0.05) and normalized by enoxaparin treatment. Conclusions. These results indicate that inflammation, coagulation, neuronal damage, and behavior are linked and may regulate each other, suggesting another pharmacological mechanism for intervention in neuroinflammation.

Keywords: enoxaparin; neuroinflammation; protease-activated receptor; thrombin.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Enoxaparin* / pharmacology
  • Inflammation / metabolism
  • Lipopolysaccharides* / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • RNA, Messenger / genetics
  • Receptor, PAR-1
  • Thrombin
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Enoxaparin
  • Lipopolysaccharides
  • RNA, Messenger
  • Receptor, PAR-1
  • Tumor Necrosis Factor-alpha
  • Thrombin

Grants and funding

This research was funded by The TELEM Rubin Excellence in Biomedical Research Program, The Chaim Sheba Medical Center, Ramat Gan, Israel.